A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma-Reference-Cited by-同舟云学术

A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma

Published:2014-01 Issue: Volume:945-946 Page:225-232
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Bennetto-Hood Chantelle,Tabolt Glenn,Savina Paul,Acosta Edward P.

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference15 articles.

1. Integrase inhibitors to treat HIV/Aids

2. Dolutegravir for the treatment of HIV

3. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

4. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

5. Dolutegravir (DTG; S/GSK1349572)+abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results – SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy;Walmsley,2012

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Genetic Variants in ABCG2, NR1I2, and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-03-01

2. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier;Fluids and Barriers of the CNS;2024-01-10

3. Therapeutic drug monitoring of antiretroviral drugs for the management of human immunodeficiency infection;Therapeutic Drug Monitoring;2024

4. Predicting the effectiveness of combination treatment of dolutegravir and fluoxetine for depressive disorders in HIV;HIV-Associated Neurocognitive Disorders;2024

5. Development of Visible Spectrophotometric Method and its Validation for Dolutegravir in Tablet Dosage Form;Asian Journal of Pharmaceutical Analysis;2023-11-23